Abstract:Objective: This study aimed to evaluate the efficacy and safety of the Meifute (R) antifungal solution on moccasin-type tinea pedis with optimal application time. Methods: A multicentered, randomized and open clinical trial was conducted by enrolling 267 patients with moccasin-type tinea pedis from 10 centers. 91 of these patients were treated with regimen A (foot bath twice per 7 days, 2 hours each time), 87 with regimen B (foot bath twice per 7 days, 1 hour each time) and 89 with regimen C (foot bath twice per 7 days, 0.5 hour each time). The evaluation of mycological effect, clinical efficacy and the overall therapeutic effect were achieved using fungus microscopic examination, fungus culture method and total symptom score. The initial valuation data were recorded as the baseline and further data were collected 1 week after the first administration (V1), 1 week after the second administration (V2) and 2 weeks after the withdrawal (V3). Results: At V3, the number of eligible patients in group A, B and C were 69, 78 and 80, respectively. There was no statistically significant difference in the fungal clearance rates (84.1%, 88.5% and 76.3%, respectively), clinical effective rate (14.5%, 28.2% and 24.1%, respectively) or integral effective rate (49.3%, 61.5% and 56.3%, respectively) among three groups. The adverse events including transient pain (31 cases, 11.6%), pain (20 cases, 7.5%), erosion (17 cases, 6.4%), pruritus (10 cases, 3.7%), burning (6 cases, 2.2%) and swelling (3 cases, 1.1%) be alleviated without any treatment. The incidence of pain and erosion in group A was significantly higher than that in group B and C. The only case of ulcer happened in group A which was cured after one-week application of Bactroban, Bifonazole, and Hirudoid. Because of the different incident of adverse reactions, there were significant difference in the dropout rates among group A, B and C (9.9%, 2.3% and 0.0%, respectively). Conclusion: The therapeutic efficacy of a 0.5 h treatment with antifungal liquid was found to be the same as that of standard application time of 2 hours. On the other hand, 0.5 h treatment protocol could reduce the incidence of adverse reactions and therefore improve the compliance of patients.

Randomized, Investigator-Masked, Controlled, Multicenter Clinical Trial of 0.25% Amorolfine Hydrochloride Cream in the Treatment of Tinea Corporis and Cruris and Tinea Pedis

Double-blind Randomized Controlled Clinical Trial of Butenafine Hydrochloride 1% Cream in the Treatment of Tinea Corporis and Cruris and Tinea Pedis

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

Efficacy and Safety of Amorolfine Lotion 0.25% w/v Compared to Amorolfine Cream 0.25% w/w in Patients With Superficial Fungal Infections of the Skin: A Multi-center, Randomized, Open-Label, Active-Controlled, Non-inferiority Phase III Clinical Trial

Evaluation of Efficacy and Safety of 2 % Sertaconazole Nitrate Cream in the Treatment of Tinea Corporis & Cruris and Tinea Pedis

Evaluation of efficacy and safety of 1％ luliconazole cream in the treatment of tinea corporis and tinea cruris

Multicenter, Double-Blind, Randomized Controlled Sdudy on Sertaconazole 2% Cream and Miconazole 2% Cream in the Treatment of Tinea Pedis and Tinea Corporis and Cruris

Evaluation of efficacy and safety of flutrimazole cream 1% in the treatment of tinea pedis

Comparison of 2 Weeks Versus 4 Weeks of Luliconazole 1％ Cream for the Treatment of Tinea Pedis: a Randomized, Double-Blind, Multicenter, Controlled Trial

Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study

A Multicentre, Randomized, Single-Blind Comparison of Topical Clindamycin 1%/benzoyl Peroxide 5% Once-Daily Gel Versus Clindamycin 1% Twice-Daily Gel in the Treatment of Mild to Moderate Acne Vulgaris in Chinese Patients.

Comparative efficacy of 1% terbinafine hydrochloride cream and 1% ciclopirox olamine cream alone and in combination for the treatment of dermatophytosis

Comparison of 1-Week Terbinafime Hydrochloride Cream, 1- and 4-Week Miconazole Nitrate Cream in the Treatment of Interdigital Tinea Pedis: a Multi-Center, Randomized and Double-Blind Study

A Multicentered, Randomized, Open Study On Efficacy And Safety Of Meifute (R) Antifungal Solution Of Optimal Application Time In Moccasin-Type Tinea Pedis

Efficacy and Safety of Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream in Chinese Patients with Melasma: a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study.

Treatment of Superficial Mycosis with Compound Bifonazole Solution: A Double-blind Controlled Clinical Trial

Experience of using the 1,5% Tetranyl U cream in patients with tinea corporis and tinea cruris

Comparison of Safety and Efficacy Between Calcipotriol Plus Betamethasone Dipropionate Gel and Calcipotriol Scalp Solution As Long-Term Treatment for Scalp Psoriasis in Chinese Patients: a National, Multicentre, Prospective, Randomized, Active-Controlled Phase 4 Trial

Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Calcipotriol Scalp Solution In The Treatment Of Scalp Psoriasis: A Randomized, Controlled Trial Investigating Efficacy And Safety In A Chinese Population

A phase III randomized controlled clinical trial evaluating the efficacy and safety of naftifine 2% cream versus terbinafine 1% cream in patients with superficial fungal infection of the skin

The Curative Effect Observation of Sertaconazole Nitrate Cream in the Treatment of Tinea Cruris